CV Sciences (CVSI) EBIT Growth (5y) (2016 - 2026)
CV Sciences (CVSI) EBIT Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | CV Sciences | 4.10 Mn | 3.84 Mn | 1.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.81% |
| Mar 31, 2026 | 36.63% |
| Dec 31, 2025 | 62.00% |
| Sep 30, 2025 | 38.60% |
| Jun 30, 2025 | 51.04% |
| Mar 31, 2025 | 14.89% |
| Dec 31, 2024 | 38.50% |
| Sep 30, 2024 | 28.09% |
| Jun 30, 2024 | -19.77% |
| Mar 31, 2024 | 41.92% |
| Dec 31, 2023 | -18.36% |
| Sep 30, 2023 | -16.26% |
| Jun 30, 2023 | -18.40% |
| Mar 31, 2023 | 53.87% |
| Dec 31, 2022 | -77.68% |
| Sep 30, 2022 | -13.11% |
| Jun 30, 2022 | -21.91% |
| Mar 31, 2022 | 16.14% |
| Dec 31, 2021 | -1.46% |
| Sep 30, 2021 | -13.53% |